Inside Cathie Wood's Gene-Editing Bet: Intellia Therapeutics Up 41% This Year

The biotech sector continues to attract bold investors willing to embrace cutting-edge innovation. Cathie Wood, CEO of Ark Invest, has built a reputation for backing companies with transformative potential—particularly in areas like gene editing, a field that promises to revolutionize how we treat previously intractable diseases. Among her portfolio picks is Intellia Therapeutics (NASDAQ: NTLA), currently ranked 25th in Ark Invest’s complete holdings list. The stock has delivered impressive early returns of 41% this year, sparking questions about whether this momentum can continue and whether it remains an attractive investment opportunity.

Why Cathie Wood’s Portfolio Includes This Gene-Editing Pioneer

Cathie Wood’s investment thesis centers on companies that can reshape industries through scientific breakthroughs. Gene editing fits squarely into that vision—it represents a potential paradigm shift in therapeutic development by enabling researchers to correct genetic abnormalities at their source. Intellia Therapeutics exemplifies this potential, developing treatments based on cutting-edge gene-modification technology.

The company’s two leading candidates—lonvo-z and nex-z—both target rare genetic diseases with limited or no existing treatment options. This strategic focus aligns with Cathie Wood’s preference for companies addressing significant unmet medical needs that could eventually serve large patient populations.

Regulatory Milestone Sparks Stock Momentum for NTLA

Recent developments have energized investor sentiment around Intellia Therapeutics. The nex-z program, designed to treat transthyretin amyloidosis, experienced a temporary setback when the FDA placed its phase 3 studies under clinical hold following a patient safety event late last year. However, regulators have now cleared one of these two studies to resume, signaling cautious optimism about the program’s viability.

This regulatory green light explains much of the stock’s strong performance in recent months. After the clinical pause depressed share prices, the pathway forward has rekindled investor interest. With one study receiving the all-clear, there’s reasonable expectation that the second paused study could also receive clearance, further supporting the recovery momentum. The fact that the FDA has taken this step suggests they believe the identified safety concerns may be manageable with adjusted protocols.

Addressing the Market Opportunity

Intellia Therapeutics management projects substantial commercial potential for its pipeline. Nex-z targets transthyretin amyloidosis, a progressive condition affecting approximately 50,000 patients with the hereditary form globally, and between 200,000 to 500,000 with the acquired variant. With no cure currently available, the company envisions nex-z as a potential one-time treatment—a paradigm that could fundamentally change disease management.

Similarly, lonvo-z addresses hereditary angioedema (HAE), a rare condition causing episodic swelling affecting roughly 150,000 patients worldwide. Management estimates the HAE market could reach $6.3 billion by 2030, while the transthyretin amyloidosis opportunity could grow to $16.8 billion in the same timeframe. These projections suggest substantial revenue potential if the company’s candidates achieve regulatory approval and market adoption.

Navigating the Risks: Gene Therapy’s Commercial Challenges

Despite the encouraging momentum, Intellia Therapeutics remains a high-risk investment. Clinical-stage biotechs in gene editing face inherent uncertainties that extend beyond regulatory approval. Even when gene-editing therapies successfully navigate the approval process, they encounter significant obstacles in real-world deployment.

Gene-editing medicines tend to be extraordinarily complex to administer and remarkably expensive to manufacture and deliver. These factors have historically limited patient access and commercial uptake, even for approved therapies with strong scientific support. Intellia Therapeutics could face identical challenges—a regulatory win may not translate into meaningful revenue if the practical and economic barriers to treatment delivery prove insurmountable.

Furthermore, the company still contends with regulatory uncertainty. Although one nex-z study received clearance, the other remains under clinical hold. Should that second study face unexpected obstacles, it could significantly constrain the program’s prospects. Beyond these specific risks, additional clinical complications could emerge during ongoing trials, potentially undermining investor confidence and share price performance.

Should You Follow Cathie Wood Into NTLA?

While Cathie Wood’s track record of identifying promising biotech innovators deserves respect, individual investors must honestly assess their risk tolerance before following her into volatile gene-therapy plays. The Motley Fool Stock Advisor team, despite identifying numerous high-conviction stock picks, notably excluded Intellia Therapeutics from their recent list of top 10 recommended stocks for investors now—a telling signal.

Intellia Therapeutics embodies the classic biotech risk-reward profile: potentially enormous upside if the science succeeds and commercial barriers fall away, but substantial downside if regulatory, clinical, or market adoption challenges materialize. For investors comfortable with significant volatility and potential capital loss, this story may warrant consideration. For most conservative investors seeking lower-risk opportunities, Intellia Therapeutics deserves a pass, regardless of its strong year-to-date performance or Cathie Wood’s portfolio inclusion.